Cited by 392CAR-T cell therapy researchMultiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Open access

Smith, Eric L., Harrington, Kim, Staehr, Mette, Masakayan, Reed, Jones, Jon, Long, Thomas J., Ng, Khong Y., Ghoddusi, Majid, Purdon, Terence J., Wang, Xiuyan, Do, Trevor, Pham, Minh Thu, Brown, Jessica M., De Larrea, Carlos Fernandez, Olson, Eric, Peguero, Elizabeth, Wang, Pei, Liu, Hong, Xu, Yiyang, Garrett-Thomson, Sarah C., Almo, Steven C., Wendel, Hans-Guido, Riviere, Isabelle, Liu, Cheng, Sather, Blythe, Brentjens, Renier J.·2019·Science Translational Medicine

DOI 10.1126/scitranslmed.aau7746PMC PMC7508042

Open this paper in CoChat — free account

Abstract

GPRC5D is an attractive target for immunotherapy of myeloma, and optimized GPRC5D-targeted CAR T cells eradicate myeloma xenografts.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aau7746

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Self-citation
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citation
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,363
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D. A., Wu, G. S., Sussman, R. T., Lanauze, C. B., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,279
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · cited 14×
“R. Gardner, D. Wu, S. Cherian, M. Fang, L.-A. Hanafi, O. Finney, H. Smithers, M. C. Jensen, S. R. Riddell, D. G. Maloney, C. J. Turtle, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.”
Influential
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Brudno, J. N., Marić, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler‐Stevenson, M., Salem, D., Yuan, C. M., Pavletic, S. Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 792

Show all 35 references

Research works printed but not linked: 1

A. D. Cohen, A. L. Garfall, E. A. Stadtmauer, S. F. Lacey, E. Lancaster, D. T. Vogl, B. M. Weiss, D. E. Ambrose, A. M. Nelson, F. Chen, G. Plesa, I. Kulikovskaya, V. Gonzalez, M. Gupta, R. M. Young, K. Dengel, L. O’keefe, S. Le, C. Richardson, R. E. Isaacs, J. J. Melenhorst, B. L. Levine, C. H. June, M. C. Milone, Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood 130, 505 (2017).

Sorted by citations

Items 201–300 of 392

Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?
Tannoury, M., Garnier, D., Susín, S. A., & Bauvois, B. (2022) · Cancers · doi:10.3390/cancers14246026 · Cited by 13
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives
Shrivastava, T., van Rhee, F., & Hadidi, S. A. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s370880 · Cited by 13
CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
Fischer, L., Grieb, N., Platzbecker, U., Vučinić, V., & Merz, M. (2023) · European Journal of Haematology · doi:10.1111/ejh.14051 · Cited by 11
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain
Meeuwsen, M. H., Wouters, A. K., Wachsmann, T. L. A., Hagedoorn, R. S., Kester, M. G. D., Remst, D. F. G., van der Steen, D. M., de Ru, A. H., van Hees, E. P., Kremer, M., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01408-6 · Cited by 12
Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy
Grywalska, E., Sosnowska-Pasiarska, B., Smok-Kalwat, J., Pasiarski, M., Niedźwiedzka-Rystwej, P., & Roliński, J. (2020) · Cells · doi:10.3390/cells9040983 · Cited by 10
Expression of activated integrin β7 in multiple myeloma patients
Hosen, N., Yoshihara, S., Takamatsu, H., Ri, M., Nagata, Y., Kosugi, H., Shimomura, Y., Hanamura, I., Fuji, S., Minauchi, K., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03162-2 · Cited by 13
Innovation in BCMA CAR-T therapy: Building beyond the Model T
Banerjee, R. K., Lee, S. S., & Cowan, A. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1070353 · Cited by 12
Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma
Mithraprabhu, S., Kalff, A., Gartlan, K. H., Savvidou, I., Khong, T. T., Ramachandran, M., Cooke, R. E., Bowen, K. M., Hill, G. R., Reynolds, J., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17080 · Cited by 12
Antibody-Based Treatment Approaches in Multiple Myeloma
Hosoya, H., & Sidana, S. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00624-6 · Cited by 12
CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
Yu, T., Jiao, J., & Wu, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1499590 · Cited by 12
Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline
Shastri, T., Trabolsi, A., Arumov, A., & Schatz, J. H. (2025) · BioDrugs · doi:10.1007/s40259-025-00735-z · Cited by 12
Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT
Garderet, L., Morris, C., Beksaç, M., Gahrton, G., Schönland, S. O., Yakoub‐Agha, I., & Hayden, P. J. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.016 · Cited by 11
Multi-targeted immunotherapeutics to treat B cell malignancies
Gambles, M. T., Yang, J., & Kopec̆ek, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.048 · Cited by 12
Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond
Kocoglu, M. H., & Badros, A. Z. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1756258 · Cited by 11
Boosting Immunity against Multiple Myeloma
Lopes, R., Ferreira, B. V., Caetano, J., Barahona, F., Carneiro, E. A., & Joao, C. M. (2021) · Cancers · doi:10.3390/cancers13061221 · Cited by 11
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
Jin, L., Gu, S., Ruan, Q., Lu, J., Qiang, W., He, H., Fan, X., Liu, J., Guo, P., Meng, X., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00176-0 · Cited by 11
Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells
Shah, U. A., & Smith, E. L. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000379 · Cited by 11
Self-citation
Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
Jindal, V., Khoury, J., Gupta, R., & Jaiyesimi, I. A. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000669 · Cited by 10
Chimeric antigen receptor T-cell therapy for multiple myeloma
Hosen, N. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02827-8 · Cited by 11
Immunotherapy in multiple myeloma: when, where, and for who?
Verkleij, C. P. M., Korst, C. L. B. M., & van de Donk, N. W. C. J. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000677 · Cited by 10
Monoclonal antibodies as an addition to current myeloma therapy strategies
Jullien, M., Touzeau, C., & Moreau, P. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1837627 · Cited by 10
The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
Straßl, I., Schreder, M., Steiner, N., Rudzki, J. D., Agis, H., Kunz, T., Müser, N., Willenbacher, W., Petzer, A. L., Neumeister, P., et al. (2021) · Cancers · doi:10.3390/cancers13184701 · Cited by 10
Modern treatments and future directions for newly diagnosed multiple myeloma patients
Lu, S. X. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101151 · Cited by 10
CAR-T Therapy in Relapsed Refractory Multiple Myeloma
Ding, H. S., & Wu, Y. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673268932230920063933 · Cited by 10
Cellular Therapies for Multiple Myeloma: Engineering Hope
Vera-Cruz, S., Culubret, M., Konetzki, V., Alb, M., Friedel, S. R., Hudecek, M., Einsele, H., Danhof, S., & Scheller, L. (2024) · Cancers · doi:10.3390/cancers16223867 · Cited by 9
MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity
Liu, M., Akahori, Y., Imai, N., Wang, L., Negishi, K., Kato, T., Fujiwara, H., Miwa, H., Shiku, H., & Miyahara, Y. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010248 · Cited by 9
CAR T-cell therapy to treat multiple myeloma: current state and future directions
Reddy, S. T., Hosoya, H., & Mikkilineni, L. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10219-1 · Cited by 10
Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials
Ormhøj, M., Abken, H., & Hadrup, S. R. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03163-y · Cited by 9
Update on the current and future use of CAR‐T to treat multiple myeloma
Gahvari, Z. J., Brunner, M., Schmidt, T. M., & Callander, N. S. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14145 · Cited by 9
A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
Tomita, U., Ishimoto, Y., Ri, M., Kawase, Y., Hizukuri, Y., Maru, C., Nanai, K., Nakamura, R., Nakayama, M., Oguchi-Oshima, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55143-0 · Cited by 9
Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma
Jeong, J., Park, J., Mo, G. Y., Shin, J. W., & Cho, Y. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168748 · Cited by 9
DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma
Neeli, P. K., Maza, P. A. M., Chai, D., Zhao, D., Hoi, X. P., Chan, K. S., Young, K. H., & Li, Y. (2024) · npj Vaccines · doi:10.1038/s41541-024-00979-w · Cited by 9
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today?
Zhou, X., Kortuem, K. M., Rasche, L., & Einsele, H. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104265 · Cited by 9
CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells
Wachsmann, T. L. A., Poortvliet, T., Meeuwsen, M. H., Remst, D. F. G., Toes, M. F., Wouters, A. K., Hagedoorn, R. S., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.035 · Cited by 11
Probing the orphan receptors: Tools and directions
Franchini, L., & Orlandi, C. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.06.011 · Cited by 9
Integrating Immune Therapies for the Treatment of Multiple Myeloma.
Mikkilineni, L., & Sidana, S. (2023) · The Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7100 · Cited by 7
Emerging role of G protein‐coupled receptor class C group 5 member D‐directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies
Wang, X., Cui, Y., Wang, Y., & Fang, B. (2025) · British Journal of Haematology · doi:10.1111/bjh.70116 · Cited by 8
Self-citation
Animal models in preclinical evaluation of CAR-T cell therapy: Advantages and limitations
Fløe, L. V. B., Pedersen, M. G., & Møller, B. K. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189455 · Cited by 9
THE ROLE OF CAR T-CELL THERAPY IN THE ERA OF BISPECIFIC ANTIBODIES
Nath, K. D., Mailankody, S., & Usmani, S. Z. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.011 · Cited by 8
BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma
Liu, Y., Zhou, Y., Nie, L., Zhu, S., Li, N., Wu, Z.-H., Wang, Q., Jian, Q., Wu, B.-Y., Chen, S., et al. (2023) · Cancers · doi:10.3390/cancers15245774 · Cited by 8
Proteasome Inhibitors in Multiple Myeloma
Mitsiades, C. S. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.016 · Cited by 9
Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy
Wang, M., Wang, C., Deng, J., Wang, H., Sun, C., Luo, S., & Hu, Y. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2906216 · Cited by 9
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Sakemura, R. L., Cox, M. J., Bansal, A., Roman, C. M., Hefazi, M., Vernon, C. J., Glynn, D. L., Pandey, M. K., DeGrado, T. R., Siegler, E. L., et al. (2022) · Journal of Visualized Experiments · doi:10.3791/62334 · Cited by 8
Current Main Topics in Multiple Myeloma
Morè, S., Corvatta, L., Manieri, V. M., Olivieri, A., & Offidani, M. (2023) · Cancers · doi:10.3390/cancers15082203 · Cited by 8
CAR T cell therapy
Hosen, N. (2020) · Immunological Medicine · doi:10.1080/25785826.2020.1796063 · Cited by 8
Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review
George, L. L., Deshpande, S., Cortese, M. J., Kendall, E. K., Chattaraj, A., Shah, Z., Zhao, J., & Anwer, F. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.06.003 · Cited by 8
CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies
Mi, J., Xu, J., Zhou, J., Zhao, W., Zhu, C. H., Melenhorst, J. J., & Chen, S. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0904-z · Cited by 8
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS
Mancuso, K., Talarico, M., Manzato, E., Barbato, S., Tacchetti, P., Zamagni, E., & Cavo, M. (2025) · Cancers · doi:10.3390/cancers17091514 · Cited by 9
Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM
Iida, S., Sunami, K., Ito, S., Yuda, J., Fujikawa, E., Takamoto, M., Aida, K., Yamazaki, H., Takahashi, M., & Ishida, T. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-03991-5 · Cited by 7
ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice
Weber, J., Rade, M., Michael, J., Tony, L. T., Freitag, F., Spieler, P., Müller, C., Kalogirou, C., Mainz, L., Lehmann, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102400 · Cited by 7
Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma
Bal, S., Htut, M., Nadeem, O., Anderson, L. D., Gregory, T. K., Kocoglu, M. H., Rossi, A., Martin, T. G., Egan, D. N., Costa, L. J., et al. (2026) · Blood · doi:10.1182/blood.2025030750 · Cited by 7
Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms
Ndacayisaba, L. J., Rappard, K. E., Shishido, S. N., Setayesh, S. M., Tang, G., Lin, P. Y., Matsumoto, N., Hsu, C.-J., Nevarez, R., Velasco, C. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113427 · Cited by 7
Current Status of CAR-T Cell Therapy in Multiple Myeloma
Reguera, J. L., García‐Guerrero, E., & Pérez‐Simón, J. A. (2021) · Hemato · doi:10.3390/hemato2040043 · Cited by 7
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma
Midha, S., Hartley-Brown, M. A., Mo, C. C., Hossain, S., Nadeem, O., O’Donnell, E., Bianchi, G., Sperling, A. S., Laubach, J. P., & Richardson, P. G. G. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2274420 · Cited by 7
Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment
Lapietra, G., Fazio, F., & Petrucci, M. T. (2022) · Biomolecules · doi:10.3390/biom12081146 · Cited by 8
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Holstein, S. A., Howard, A., Avigan, D., Bhutani, M., Cohen, A. D., Costa, L. J., Dhodapkar, M. V., Gay, F., Gormley, N. J., Green, D. J., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.06.011 · Cited by 7
DNA self-assembly-mediated high drug-antibody ratio ADC platform for targeted tumor therapy and imaging
Jin, S., Zhuang, X., Xu, Y., Nie, G., Chen, S., & Pan, L. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102459 · Cited by 6
Self-citation
Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report
He, X., Zhang, X., Yu, Z., Meng, J., Jiang, Y., Zhao, Y., Lyu, H., Bai, X., Xiao, X., & Zhao, M. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014982 · Cited by 6
Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence
Moore, D. C., Elsey, G., McElwee, J., & Atrash, S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2595122 · Cited by 6
RAMIHM generates fully human monoclonal antibodies by rapid mRNA immunization of humanized mice and BCR-seq
Ren, P., Peng, L., Yang, L., Suzuki, K., Fang, Z., Renauer, P. A., Lin, Q., Bai, M., Li, T., Clark, P. R., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2022.12.005 · Cited by 6
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead
Mouhieddine, T. H., Costa, B. A., & Richter, J. R. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.12.001 · Cited by 6
Structure and function of therapeutic antibodies approved by the US FDA in 2025
Strohl, W. R. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag027 · Cited by 6
GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?
Gagelmann, N., & Brudno, J. N. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00385-4 · Cited by 6
Targeting GPRC5D in multiple myeloma
Elemian, S., & al Hadidi, S. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2343114 · Cited by 7
Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple Myeloma
Louvet, C., Nadeem, O., & Smith, E. L. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0073 · Cited by 6
Self-citation
SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM
Jurgens, E. M., & Usmani, S. Z. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.01.001 · Cited by 6
Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma
Meo, F. D., Albano, F., Cesarano, A., Wang, Y., Kale, B. J., Shain, K. H., Silva, A., Kurihara, N., Tenshin, H., Jellyman, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.007 · Cited by 5
Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies
Zhou, S., Yang, Y., Jing, Y., & Zhu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1435635 · Cited by 5
Bispecific Antibodies in the Treatment of Multiple Myeloma
Zhou, X., Xiao, X., Kortuem, K. M., & Einsele, H. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.003 · Cited by 5
Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D ‐ CAR T cells
Hu, X., Zhou, X., Zhao, Q., Yang, Y., Liang, Y., Xiao, Y., Liu, Z., Liu, L., Zhang, C., & Du, J. (2024) · British Journal of Haematology · doi:10.1111/bjh.19739 · Cited by 5
Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma
Yan, S., Ming, X., Zheng, R., Zhu, X., & Xiao, Y. (2025) · Cancer Medicine · doi:10.1002/cam4.70764 · Cited by 5
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review
Pan, D., Kumar, A. D., Lipof, J. J., Chung, A., Wolf, J. L., Martin, T. G., Arora, S., Sayre, P. H., & Chari, A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2511179 · Cited by 5
Engineered NKG2C+ CD8+ TKLR cells exhibit effective antitumor control in mice while mitigating cytokine release syndrome
Lupo, K. B., Panjwani, M. K., Halawi, A. G., Shahid, S., Sottile, R., Lawry, C., Kolk, G., Kontopoulos, T., Daniyan, A. F., Chandran, S. S., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci193053 · Cited by 5
CAR T cells targeting options in the fight against multiple myeloma
Nicolini, F., Bravaccini, S., Mazza, M., Gruszka, A., Tazzari, M., Martín-Antonio, B., Juan, M., Ibrahim, T., Maltoni, R., Martinelli, G., et al. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04146-4 · Cited by 5
Chimeric Antigen Receptor T Cells for Multiple Myeloma
Cowan, A. J., Tuazon, S. A., Portuguese, A. J., & Green, D. J. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000506 · Cited by 5
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Wang, X., Pan, B., Huang, H., & Xu, K. (2021) · ImmunoMedicine · doi:10.1002/imed.1030 · Cited by 5
Self-citation
CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity
Krejčí, M., Adam, Z., Krejčí, M., Pour, L., Sandecká, V., & Štork, M. (2022) · Neoplasma · doi:10.4149/neo_2022_220504n477 · Cited by 5
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma
Stock, S., Fertig, L., Gottschlich, A., Dörr, J., Märkl, F., Majed, L., Menkhoff, V. D., Grünmeier, R., Rejeski, K., dos Santos, D. M. C., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03688-4 · Cited by 4
CAR-T Therapy in Multiple Myeloma: Looking Beyond
Maiorana, G., Antolino, G., Verde, G. L., & Tafuri, A. (2024) · Hemato · doi:10.3390/hemato5020015 · Cited by 4
Rapidly Manufactured CAR-T with Conserved Cell Stemness and Distinctive Cytokine-Secreting Profile Shows Improved Anti-Tumor Efficacy
Tsao, S.-T., Gu, M., Xiong, Q., Deng, Y., Deng, T., Fu, C., Zhao, Z., Zhang, H., Liu, C., Zhong, X., et al. (2024) · Vaccines · doi:10.3390/vaccines12121348 · Cited by 4
Self-citation
Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
Yang, X., Wang, F., Yuan, X., Yang, B., Chen, J., Cheng, J., Liu, G., Tang, D., Xu, X., Wang, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1466443 · Cited by 4
Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma
Li, W., Xiao, X., Jing, X., Zheng, Y., Sun, X., Bai, W., Li, M., Luo, M., & Xiao, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1607778 · Cited by 4
Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 study
Ito, S., Kuroda, Y., Sunami, K., Matsue, K., Imada, K., Tamura, H., Fujikawa, E., Yamazaki, H., Takamoto, M., Pei, L., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04134-6 · Cited by 4
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?
Segers, F., & Delforge, M. (2026) · Targeted Oncology · doi:10.1007/s11523-025-01189-7 · Cited by 4
T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma.
Bezverbnaya, K., Hammill, J. A., Cummings, D. T., Bojovic, B., Groisman, B., Baker, C., Aarts, C. W., Hayes, D. L., Rill, D., Xu, S. X., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.01.002 · Cited by 4
Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy
Wang, M., Jia, L., Dai, X., & Zhang, X. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13621 · Cited by 5
Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells
Narra, R., Peshin, S., & Dhakal, B. (2024) · Acta Haematologica · doi:10.1159/000543265 · Cited by 5
A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy
Robat-Jazi, B., Mahalleh, M., Dashti, M., Nejati, N., Ahmadpour, M., Alinejad, E., Mohammadi, S., Lorestani, P., Hamidieh, A. A., Habibi, M. A., et al. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206350342241224073809 · Cited by 4
Preclinical testing of CAR T cells in zebrafish xenografts
Grissenberger, S., Salzer, B., Pascoal, S., Wenninger-Weinzierl, A., Lehner, M., & Distel, M. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.07.002 · Cited by 4
Antigen-specific T cell immunotherapy by in vivo mRNA deliveryPreprint
Su, F., Siebart, J. C., Chan, C. S., Wang, M. Y., Yao, X., Trenkle, A. S., Sivakumar, A., Su, M., Harandi, R., Shahrawat, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.29.620946 · Cited by 6
Bridging biomaterials and immunotherapy: hydrogel strategies for next-generation CAR-T cell treatment
Shojaei, S., Sani, M., Azarpira, N., Latifi, M., & Sani, F. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04993-8 · Cited by 3
Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma
Mailankody, S., Mitra, S., Herrera, K., Ziccheddu, B., Cadzin, B., Eren, Ö. C., Farzana, T., Ullah, T., Landa, J., Derkach, A., et al. (2026) · Blood · doi:10.1182/blood.2025032122 · Cited by 3
Self-citation
Biology of CAR-T Cells
Berger, T. R., Boardman, A., Brentjens, R. J., & Maus, M. V. (2021) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_3 · Cited by 3
Self-citation
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?
Li, C., & Mei, H. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00205-9 · Cited by 3
Advancements in the design and function of bispecific CAR-T cells targeting B Cell-Associated tumor antigens
Sima, H., & Shao, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113166 · Cited by 3
Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups
Liu, E., Jaouadi, O., Sharma, R., Becker, N. J., Johnson, T. S., Sudha, P., Chopra, V. S., Zafar, F., Hamidi, H., Pawlyn, C., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01503-y · Cited by 3
CAR-T Therapy of Multiple Myeloma, Based on the Congresses ASH-2021 and ASCO-2022
Семочкин, С. В. (2023) · Clinical oncohematology · doi:10.21320/2500-2139-2023-16-1-1-13 · Cited by 4
An Unusual Case of Low Vision and Anisocoria Considered a Neurological Finding in the Emergency Department: Ocular Siderosis
Özen, O., & Özen, M. İ. (2025) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.galenos.2024.77783 · Cited by 3
Multitargeted CAR T-cell therapy in multiple myeloma
Susanibar-Adaniya, S. P., & Garfall, A. L. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30165-6 · Cited by 3
GPRC5D: The Next Frontier for Immunotherapy in Multiple Myeloma
Bhutani, M., & Usmani, S. (2023) · The Hematologist · doi:10.1182/hem.v20.1.202314 · Cited by 3

Authors: Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., Do, T., Pham, M. T., Brown, J. M., De Larrea, C. F., Olson, E., Peguero, E., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S. C., Almo, S. C., Wendel, H.-G., Riviere, I., Liu, C., Sather, B., & Brentjens, R. J.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Juno Therapeutics (United States) (US)
Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sloan Kettering Institute, New York, NY 10065, USA.
Eureka Therapeutics (United States) (US)
Albert Einstein College of Medicine (US)
Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eureka Therapeutics, Emeryville, CA 94608, USA.
Corresponding author: Brentjens, Renier J.
ORCID: Smith, Eric L.
Staehr, Mette
Masakayan, Reed
Jones, Jon
Ng, Khong Y.
Ghoddusi, Majid
Purdon, Terence J.
Wang, Xiuyan
Brown, Jessica M.
Peguero, Elizabeth
Garrett-Thomson, Sarah C.
Almo, Steven C.
Wendel, Hans-Guido
Sather, Blythe
Brentjens, Renier J.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2019-03-27
Volume: 11
Issue: 485
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.aau7746
PMC: PMC7508042
OpenAlex: W2923396001
Cited by: 391
References: 35
Citations by year: 2026: 31 · 2025: 55 · 2024: 79 · 2023: 68 · 2022: 46 · 2021: 55 · 2020: 42 · 2019: 14
FWCI: 16.36
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (R01 CA198095, R01 HG008325)
National Cancer Institute (P30 CA008748, U54 OD020355-01, PO1 CA190174-01, P01 CA059350, P30 CA013330, R01 CA138738-05)
Multiple Myeloma Research Foundation
American Society of Hematology
Leukemia and Lymphoma Society
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords: GPRC5D, multiple myeloma, CAR T-cell therapy, BCMA, scFv, phage display
MeSH terms: Receptors, Chimeric Antigen, Animals, Antibody Specificity, Humans, Multiple Myeloma, RNA, Messenger, Gene Expression, Immunotherapy, Adoptive, Mice, SCID, Mice, Inbred NOD, Xenograft Model Antitumor Assays, Receptors, G-Protein-Coupled, Cell Line, Tumor, Mice, B-Cell Maturation Antigen, Single-Chain Antibodies, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks